Recommend Epigenetics to your librarian today. Download form here.
Sign up for Table of Contents Alerts.
The official journal of the Epigenetics Society.
Email this page
Print this page
Meeting Report
A work in progress: The clinical development of histone deacetylase inhibitor
Silvia Marsoni, Giovanna Damia and Gabriella Camboni
volume 3 | issue 3
May/June 2008Pages: 164 - 172
Subscribe to this journal for $79/year
It has been widely recognized that histone deacetylases (HDAC) are promising targets in the field of oncology. An impressive body of preclinical research points to the ability of HDAC inhibitors (HDACIs) to modulate a wide variety of cellular functions, including cell differentiation, cell cycle progression, apoptosis, cytoskeletal modifications, and angiogenesis. Originally developed as epigenetic drugs because of their ability to inhibit histones deacetylation, HDACIs are now being considered also because of their effects on other acetylation-regulated proteins with pivotal roles in transformed cells. This review will highlight the clinical development of HDACIs in oncology and will try to discuss the several major open clinical issues challenging the successful clinical development of HDACIs, with a particular emphasis on the spectrum of activity of these agents, the best development strategy in solid tumours, the cardiac side effects and bio-markers to be used in clinical trials.
Authors
Silvia Marsoni
SENDO Foundation
Giovanna Damia
Istituto di Ricerche Farmacologiche
Gabriella Camboni
EOS S.p.A.